| Molecular dynamics simulations in drug discovery and pharmaceutical development OMH Salo-Ahen, I Alanko, R Bhadane, AMJJ Bonvin, RV Honorato, ... Processes 9 (1), 71, 2020 | 350 | 2020 |
| Computational approaches to identifying and characterizing protein binding sites for ligand design S Henrich, OMH Salo‐Ahen, B Huang, FF Rippmann, G Cruciani, ... Journal of Molecular Recognition: An Interdisciplinary Journal 23 (2), 209-219, 2010 | 262 | 2010 |
| Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes SM Saario, OMH Salo, T Nevalainen, A Poso, JT Laitinen, T Järvinen, ... Chemistry & biology 12 (6), 649-656, 2005 | 195 | 2005 |
| Towards peptide vaccines against Zika virus: Immunoinformatics combined with molecular dynamics simulations to predict antigenic epitopes of Zika viral proteins M Usman Mirza, S Rafique, A Ali, M Munir, N Ikram, A Manan, ... Scientific reports 6 (1), 37313, 2016 | 135 | 2016 |
| Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro MA Alamri, M Tahir ul Qamar, MU Mirza, R Bhadane, SM Alqahtani, ... Journal of Biomolecular Structure and Dynamics 39 (13), 4936-4948, 2021 | 111 | 2021 |
| Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase D Cardinale, G Guaitoli, D Tondi, R Luciani, S Henrich, OMH Salo-Ahen, ... Proceedings of the National Academy of Sciences 108 (34), E542-E549, 2011 | 107 | 2011 |
| Development of a 3D model for the human cannabinoid CB1 receptor OMH Salo, M Lahtela-Kakkonen, J Gynther, T Järvinen, A Poso Journal of medicinal chemistry 47 (12), 3048-3057, 2004 | 105 | 2004 |
| Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands KH Raitio, OMH Salo, T Nevalainen, A Poso, T Jarvinen Current medicinal chemistry 12 (10), 1217-1237, 2005 | 86 | 2005 |
| CB receptor ligands from plants R Bauer, K Woelkart, OMH Salo-Ahen Current Topics in Medicinal Chemistry 8 (3), 173-186, 2008 | 79 | 2008 |
| Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor OMH Salo, KH Raitio, JR Savinainen, T Nevalainen, M Lahtela-Kakkonen, ... Journal of medicinal chemistry 48 (23), 7166-7171, 2005 | 77 | 2005 |
| Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system SM Saario, A Poso, RO Juvonen, T Järvinen, OMH Salo-Ahen Journal of medicinal chemistry 49 (15), 4650-4656, 2006 | 76 | 2006 |
| Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis B Jabbar, S Rafique, OMH Salo-Ahen, A Ali, M Munir, M Idrees, MU Mirza, ... Frontiers in Immunology (Viral Immunology) 9 (Article 3000), 10.3389/fimmu …, 2018 | 63 | 2018 |
| Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs D Garg, S Henrich, OMH Salo-Ahen, H Myllykallio, MP Costi, RC Wade Journal of medicinal chemistry 53 (18), 6539-6549, 2010 | 63 | 2010 |
| Identification of WIN55212‐3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor JR Savinainen, T Kokkola, OMH Salo, A Poso, T Järvinen, JT Laitinen British journal of pharmacology 145 (5), 636-645, 2005 | 57 | 2005 |
| Homodimeric enzymes as drug targets D Cardinale, OMH Salo-Ahen, S Ferrari, G Ponterini, G Cruciani, ... Current medicinal chemistry 17 (9), 826-846, 2010 | 55 | 2010 |
| Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems C Sahlgren, A Meinander, H Zhang, F Cheng, M Preis, C Xu, TA Salminen, ... Advanced healthcare materials, 2017 | 43 | 2017 |
| Dynamics of CYP51: implications for function and inhibitor design X Yu, V Cojocaru, G Mustafa, OMH Salo‐Ahen, GI Lepesheva, RC Wade Journal of Molecular Recognition 28 (2), 59-73, 2015 | 40 | 2015 |
| Inhibition of oncogenic kinases: an in vitro validated computational approach identified potential multi-target anticancer compounds N Ikram, MU Mirza, M Vanmeert, M Froeyen, OMH Salo-Ahen, M Tahir, ... Biomolecules 9 (4), 124, 2019 | 35 | 2019 |
| Hotspots in an obligate homodimeric anticancer target. Structural and functional effects of interfacial mutations in human thymidylate synthase OMH Salo-Ahen, A Tochowicz, C Pozzi, D Cardinale, S Ferrari, Y Boum, ... Journal of medicinal chemistry 58 (8), 3572-3581, 2015 | 30 | 2015 |
| Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore‐based virtual screening approach MU Mirza, A Saadabadi, M Vanmeert, OMH Salo-Ahen, I Abdullah, ... European Journal of Pharmaceutical Sciences 155, 105537, 2020 | 29 | 2020 |
Rebecca WadeHeidelberg Institute for Theoretical Studies and Heidelberg UniversityEmail verificata su h-its.org
